Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Efficacy and Safety Study of Cluster of Differentiation 19 (CD19)-Targeted CART (CD19CART) Therapy for CD19 Positive Relapsed or Refractory B-cell Hematologic Malignancies (SCT019-01）

NCT02813837 is registered in ClinicalTrials.gov with Innovative Cellular Therapeutics Co., Ltd. as lead sponsor.

NCT NCT02813837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02813837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Efficacy and Safety Study of Cluster of Differentiation 19 (CD19)-Targeted CART (CD19CART) Therapy for CD19 Positive Relapsed or Refractory B-cell Hematologic Malignancies (SCT019-01）
Lead sponsor
Innovative Cellular Therapeutics Co., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
June 30, 2015
Completion date
July 31, 2021
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, b-cell, lymphoma, b-cell